3月6日 - ** 券商H.C. Wainwright开始对癌症疗法生产商 ImmunityBio IBRX.O进行评级，给予 "买入 "评级，目标价为8美元；与该股上次收盘价相比，上涨了161%。
** 券商称该公司的膀胱癌疗法Anktiva有望在2025年迎来 "引人注目的增长机会"；预计到2034年销售额将达到43亿美元。
** 认为 Anktiva可以 成为一种应用广泛的 "骨干疗法"，但其价值 "被严重低估"。
** Anktiva+卡介苗 的完全应答率最高，达到62%，超过了默克公司MRK.N的Keytruda和Ferring公司的Adstiladrin等竞争对手。
** 上个月，FDA 授权 (link) co 的新版卡介苗用于治疗膀胱癌。
** 2024 年，IBRX 下跌 ~51
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.